Inovio Pharmaceuticals

(INO) Inovio Pharmaceuticals Inc

Last updated:

October 12, 2021 at 11.41am

Company Overview:

A biotechnology company, Inovio Pharmaceuticals focuses on the discovery, development and commercialisation of DNA medicines that serve to treat, cure and protect from diseases primarily associated with human papillomavirus (HPV), cancer and infectious diseases. Inovio’s technology is based on mRNA technology, whereby engineered DNA is inserted into the cells, where it becomes transcribed into mRNA and then translated into proteins. The proteins encoded by the DNA evoke an immune response to antigens from cancers and viruses by stimulating the production of T cells and antibodies that help with recovery.  
 
Its SynCon immunotherapy design is known for having the ability to break the immune system’s tolerance of cancerous cells and as a result, promote cross-strain protection against unmatched and matched pathogens. On the other hand, Inocio’s CELLECTRA delivery system facilitates optimised cellular uptake of the SynCon immunotherapies.